Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Etms Treatment topic
No spam. Unsubscribe anytime.
Wave Neuroscience tells committee eTMS showed large symptom drops and may reduce opioid cravings
Summary
Wave Neuroscience and providers described EEG‑guided TMS (eTMS) as a promising treatment for PTSD and substance use disorder, cited an FDA breakthrough designation (Nov. 2024) and reported program metrics including roughly 835 treated patients and a 63% reduction on a PTSD symptom scale in program data; providers asked for state funding and wider deployment.
Wave Neuroscience and contracted treatment providers briefed the Local Government, Public Safety and Veterans Affairs Committee on EEG‑guided transcranial magnetic stimulation (eTMS) and local pilot results for PTSD and substance use disorder.
Dr. Juan, representing Wave Neuroscience, described the clinical process: obtain an EEG brain map, identify disrupted regions via computational analytics, then target those areas with transcranial magnetic stimulation. He told the committee that the technology received an FDA "breakthrough device" designation in November 2024 and presented program outcomes from the state's deployment: about 835 patients treated, more than 2,600 EEGs performed and roughly 4,000 clinical scales collected. Dr. Juan said program data show a 63% improvement in PCL‑5 PTSD scores for eTMS patients and reported reductions in opioid and alcohol cravings in pilot inpatient populations, including a reported 72% reduction in fentanyl‑related craving measures in one cohort.
Teresa Kane, executive director of Perry Behavioral Health Choices, which holds the state contract for eTMS services in her region, described a family case in which her brother began eTMS in early February and showed rapid improvements in sleep, memory and daily functioning over the course of treatment. Kane said local pilots have treated people with methamphetamine, cocaine and opioid disorders and recommended expanding funding and referral pathways. Committee members asked about methamphetamine results and about how patients and first responders can access the service; witnesses said a statewide portal (ETMS Ohio) and local veterans service commissions can facilitate referrals.
No committee vote or directive followed the presentation; the committee thanked presenters and placed written testimony from Meridian Healthcare in the record.
